Pages that link to "Q83154076"
Jump to navigation
Jump to search
The following pages link to Effects of intravenous iron on mononuclear cells during the haemodialysis session (Q83154076):
Displaying 16 items.
- Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis (Q28547636) (← links)
- Kidney-brain crosstalk in the acute and chronic setting (Q30278845) (← links)
- Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study (Q30588674) (← links)
- Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients (Q35041088) (← links)
- Intravenous iron administration and hypophosphatemia in clinical practice (Q35591336) (← links)
- The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients (Q37542851) (← links)
- How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider. (Q38142892) (← links)
- Ferric carboxymaltose: a review of its use in iron deficiency (Q38271890) (← links)
- Distinct immunologic effects of different intravenous iron preparations on monocytes (Q38541320) (← links)
- What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Balancing Benefits and Safety with Intravenous Iron Treatment (Q40526919) (← links)
- Serum ferritin is associated with arterial stiffness in hemodialysis patients: results of a 3-year follow-up study (Q46676046) (← links)
- Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound (Q49300014) (← links)
- Medication practice in hospitals: are nanosimilars evaluated and substituted correctly? (Q52337431) (← links)
- Intravenous Irons: From Basic Science to Clinical Practice (Q57167424) (← links)
- Genomic damage as a biomarker of chronic kidney disease status. (Q64904551) (← links)
- In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulations (Q88950803) (← links)